Actinium Pharmaceuticals Partners for Ac-225 Supply
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), recognized as a leader in the creation of targeted radiotherapies, has recently entered into a pivotal supply agreement with Eckert & Ziegler. This collaboration aims to secure a dependable supply of Actinium-225 (Ac-225), a critical isotope that will support Actinium's extensive portfolio of developmental therapies.
Promise of Targeted Radiotherapy
The use of Ac-225 in targeted radiotherapy has shown remarkable efficacy in treating various forms of cancer. Due to its ability to emit potent alpha particles with heightened energy, it effectively targets tumor cells while sparing adjacent healthy tissues. This characteristic of Ac-225 makes it particularly valuable for treating challenging cases, including micrometastases. Notably, Actimab-A, which targets CD33, exhibits promise for treating patients with acute myeloid leukemia (AML) and other related conditions.
Investment in Cutting-Edge Therapies
Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, expressed optimism about the collaboration: "Targeted radiation therapy with Ac-225 is among the most promising strategies for patients suffering from myeloid malignancies and solid tumors. Our prime initiative is to push Actimab-A into pivotal trials for patients with relapsed or refractory AML, as well as conducting frontline trials in partnership with the National Cancer Institute. Furthermore, our solid tumor research combining Actimab-A with PD-1 inhibitors continues to expand our mission."
Commitment from Eckert & Ziegler
In a statement reflecting their commitment, Dr. Harald Hasselmann, CEO of Eckert & Ziegler, highlighted the significance of their partnership with Actinium. "We are thrilled to be part of this journey to broaden the applications for Actium-225, particularly as we aim to address the ongoing challenges related to the global supply of this crucial radionuclide."
Expertise in Isotope Supply
Eckert & Ziegler has solidified its reputation as a reliable supplier of various medical isotopes, including Gallium-68, Lutetium-177, Yttrium-90, and now Actinium-225. Their robust capabilities in isotope production and comprehensive logistical experience stand to benefit pharmaceutical entities and research bodies worldwide. This collaboration ensures that Actinium has continuous access to the necessary materials required for their ongoing and future projects.
About Eckert & Ziegler and Actinium Pharmaceuticals
Eckert & Ziegler SE, home to over 1,000 professionals, is recognized for its extensive services and products related to nuclear medicine. Their contributions range from the early stages of product development to manufacturing and distribution.
Their mission aligns with Actinium’s goal of improving patient care. Actinium Pharmaceuticals remains committed to advancing its lead radiotherapy candidate, Actimab-A, which utilizes Ac-225 to target CD33 to achieve meaningful results in treatment strategies. It focuses on significant health needs and is actively participating in clinical trials in partnership with NCI.
Innovative Therapies and Future Directions
Actinium is also developing Iomab-ACT, aiming to enhance access to innovative treatments for patients undergoing cellular and gene therapies, while Iomab-B serves as a conditioning agent for patients undergoing bone marrow transplants. With over 230 patents, Actinium is well-positioned to lead in the development of therapies intended to tackle a variety of treatments.
Frequently Asked Questions
What is the purpose of the supply agreement between Actinium and Eckert & Ziegler?
The agreement aims to ensure a steady supply of Actinium-225, crucial for advancing Actinium's clinical development efforts.
How does Ac-225 radiotherapy benefit cancer patients?
Ac-225 enables precise targeting of tumor cells, allowing effective treatment while minimizing damage to surrounding healthy tissues.
What specific treatments are included in Actinium's pipeline?
Actinium is focused on Actimab-A, which targets CD33 in AML, as well as research into therapies for solid tumors in combination with PD-1 checkpoint inhibitors.
Who leads Actinium Pharmaceuticals?
Sandesh Seth is the Chairman and CEO of Actinium Pharmaceuticals, driving their innovative research and development initiatives.
Where can I find more information about Actinium Pharmaceuticals?
For further details, you can visit Actinium Pharmaceuticals’ official website.
